Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can two advanced heart maps guide a more precise fix for dangerous arrhythmias?

NCT ID NCT07746336

Disease control Sponsor: Hospital Clinic of Barcelona Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Aug 26, 2026 · Updated 3 times

Summary

This trial tests whether combining two advanced heart-mapping technologies can make ablation for ventricular tachycardia (VT) more accurate and effective. The approach merges a non-invasive 3D electrical map of the heart with detailed scar imaging from an MRI, aiming to better target the abnormal tissue causing the arrhythmia. The study enrolls adults with structural heart disease who are scheduled for VT ablation, and it will track whether the combined mapping reduces VT recurrence and improves procedural success.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A combined mapping workflow using two CE-marked devices: ADAS 3D, which analyzes cardiac MRI to characterize scar tissue, and ACORYS, which performs non-invasive electrocardiographic mapping to guide and verify ventricular tachycardia ablation.
What this could lead to
If successful, this approach could make ventricular tachycardia ablation more precise, potentially reducing the chance of the arrhythmia returning and improving long-term outcomes for people with structural heart disease.
What could go wrong
This is a relatively small, early-stage feasibility study, so results may not apply broadly. The added complexity of combining two mapping systems could also introduce technical challenges or longer procedure times.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Age ≥18 years. * Diagnosis of structural heart disease (ischemic or non-ischemic cardiomyopathy). * Documented sustained monomorphic VT (clinical or inducible), or recurrent ICD therapies for VT. * Scheduled for catheter ablation of VT according to current international guidelines. * Ability to provide written informed consent. * Ability to remain upright or seated to allow a video for 3D torso reconstruction for ECGi acquisition. Exclusion criteria * Age \<18 years. * Pregnant or breastfeeding women. * Inability to provide informed consent due to physical or mental condition. * Contraindication to computed tomography or cardiac magnetic resonance (magnetic resonance imaging-incompatible devices, claustrophobia). * Contraindication to contrast agents (gadolinium allergy or severe renal dysfunction with estimated glomerular filtration rate \<30 mL/min/1.73 m²). * Inability to remain upright for torso 3D reconstruction required for ECGi. * Life expectancy \<1 year due to non-cardiac comorbidity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arrhythmic burden are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arrhythmic burden Implantable cardioverter-defibrillator (ICD) therapies Slow-conduction substrate VT ablation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Clinic, University of Barcelona

    RECRUITING

    Barcelona, 08036, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.